Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,2-Dichloroethane SCHEMBL11148269 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL28055422 | 0.90 | TSHR (0.57) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL28748446 | 0.89 | TSHR (0.71) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL8600029 | 0.89 | TSHR (0.71) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL15167 | 0.89 | — | — | |
| SCHEMBL439119 | 0.89 | TSHR (0.71) | TSHRCYP3A4MEN1THRBHTT | |
| Ethylene Glycol SCHEMBL28253221 | 0.89 | TSHR (0.71) | TSHRCYP3A4MEN1THRBHTT | |
| SCHEMBL6947651 | 0.88 | — | — | |
| SCHEMBL3120108 | 0.88 | — | — | |
| Butyl Chloride SCHEMBL9486719 | 0.88 | TSHR (0.65) | TSHRCYP3A4MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996430-B1 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES INC (US) | 2002-11-27 | — | — | EP | claimed |
| US-6451340-B1 | CRYSTALLINE ADEFOVIR DIPIVOXIL | GILEAD SCIENCES, INC. | 2002-09-17 | — | — | US | claimed |
| US-20020045599-A1 | Nucleotide analog compositions | GILEAD SCIENCES, INC. | 2002-04-18 | — | — | US | claimed |
| EP-0996430-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | claimed |
| EP-1256584-B1 | Process for preparing Adefovir Dipivoxil | GILEAD SCIENCES INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-0985672-B1 | Method for purifying tetrakis(fluoroaryl)borate compounds | NIPPON CATALYTIC CHEM IND (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-0996430-B1 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1256584-A1 | Process for preparing adefovir dipivoxil | GILEAD SCIENCES, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| EP-1256585-A1 | Process fot preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine | GILEAD SCIENCES, INC. (US) | 2002-11-13 | — | — | EP | disclosed |
| US-6451340-B1 | CRYSTALLINE ADEFOVIR DIPIVOXIL | GILEAD SCIENCES, INC. | 2002-09-17 | — | — | US | disclosed |
| US-20020045599-A1 | Nucleotide analog compositions | GILEAD SCIENCES, INC. | 2002-04-18 | — | — | US | disclosed |
| US-6281389-B1 | MIXING WITH SOLVENT; DISTILLATION | NIPPON SHOKUBAI CO., LTD. (JP) | 2001-08-28 | — | — | US | disclosed |
| CN-1056836-C | 3,5-disubstituted and 3,4,5-trisubstituted 2-isoxazolines and isoxazoles, process for preparing same and their use as medicaments | HOECHST AG (DE) | 2000-09-27 | — | — | CN | disclosed |
| EP-0996430-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0985672-A2 | Method for purifying tetrakis(fluoroaryl)borate compounds | Nippon Shokubai Co., Ltd. (JP) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999004774-A2 | NUCLEOTIDE ANALOG COMPOSITIONS | GILEAD SCIENCES, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| CN-1143956-A | 3,5-disubstituted and 3,4,5-trisubstituted 2-isoxazolines and isoxazoles, process for preparing same and their use as medicaments | HOECHST AG (DE) | 1997-02-26 | — | — | CN | disclosed |
| US-3963629-A | SOLUBILIZERS, WATER, PROPELLANTS, FOAMS | CENTER FOR NEW PRODUCT DEVELOPMENT (US) | 1976-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045599-A1 | Nucleotide analog compositions | NUDT1, PNP, TYMP | TSHR 4705/4885CYP3A4 492/4885MEN1 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.